UNSPSC 51144116: Dimethylamphetamine or dimetamfetamine or n,n-dimethylamphetamine

This classification denotes a cns stimulant with the molecular formula C11H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 92M4C245D1, chemically known as (s)-n,n,alpha-trimethylphenethylamine but more generally known as dimetamfetamine, which bears US NIH Compound Identifier 65682. European Medicines Agency schedules Dimetamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07169MIG. The term DIMETAMFETAMINE is an International Non-Proprietary Name.

DIMETAMFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(CC1=CC=CC=C1)N(C)C.

UNSPSC 51144116 Dimethylamphetamine or dimetamfetamine or n,n-dimethylamphetamine is a Commodity code that shows minimal direct alignment with recent state and local procurement activity. The three most recent opportunities tagged to this code actually solicit naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program capabilities—none of which are dimethylamphetamine or controlled precursor compounds. State and local governments do not appear to be procuring dimethylamphetamine itself under this code. The mismatch suggests either systematic miscoding in the source data or that the code is not currently in active use for state and local purchasing.

The issuing bodies in the recent record include Seminole County, Florida (health and human services procurement), the Texas Health and Human Services Commission (pharmacy benefit program intelligence gathering), and the Minnesota Multistate Cooperative Purchasing Alliance (multi-state generic pharmaceutical contracting). Geographic activity centers on Florida, Texas, and Minnesota. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually; the Texas HHS RFI (HHS0017013, posted April 3, 2026) explored direct-to-manufacturer prescription capabilities; and the Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) sought generic pharmaceuticals and OTC products across participating state and local facilities. This code does not appear to reflect current state and local procurement demand for the product its name describes.